Aquestive Therapeutics Advances Anaphylm NDA Resubmission with Positive FDA Type A Meeting Outcome

summarizeSummary

Aquestive Therapeutics successfully completed a Type A meeting with the FDA for its Anaphylm NDA resubmission, receiving clarifying feedback and reaffirming a Q3 2026 resubmission timeline.

check_boxKey Events

• Successful FDA Type A Meeting for Anaphylm

  Aquestive Therapeutics completed an in-person Type A meeting with the FDA regarding the New Drug Application (NDA) resubmission for Anaphylm, its sublingual film for anaphylaxis.

• Clarifying Feedback Received

  The company received preliminary comments and clarifying feedback from the FDA on pharmacokinetic (PK) and human factor (HF) study designs, indicating a clear path forward.

• Q3 2026 NDA Resubmission Reaffirmed

  Aquestive Therapeutics reaffirmed its guidance to resubmit the Anaphylm NDA in the third quarter of 2026, providing a concrete timeline for this key product.

• Alignment on Key Study Elements

  The company and FDA aligned on key HF study elements and the approach to PK study design, including using labeling language for potential chewing instead of additional clinical data.

auto_awesomeAnalysis

This 8-K provides a significant positive update on Aquestive Therapeutics' key drug candidate, Anaphylm, following a prior FDA approval delay. The successful completion of a Type A meeting with the FDA, including clarifying feedback on pharmacokinetic and human factor study designs, significantly de-risks the regulatory pathway. The reaffirmation of a Q3 2026 NDA resubmission timeline provides investors with increased clarity and confidence in the program's progression. This development is crucial for the company, especially given the previous negative news regarding the Anaphylm delay in the recent 10-K, and positions Anaphylm as a potential first-in-class oral epinephrine product.